- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Assessing Orchestra BioMed Holdings: Insights From 4 Financial Analysts | 1 | Benzinga.com | ||
| 10.12.25 | TD Cowen initiates Orchestra BioMed stock with Buy rating on novel medical device portfolio | 1 | Investing.com | ||
| 08.12.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting | 127 | GlobeNewswire (Europe) | Joint presentation by Orchestra BioMed and Medtronic leadership to discuss ongoing strategic collaboration for development and commercialization of AVIM Therapy for treatment of uncontrolled hypertension... ► Artikel lesen | |
| 26.11.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 13.11.25 | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 10.11.25 | Orchestra BioMed Holdings Q3 Loss Widens | 1 | RTTNews | ||
| 10.11.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates | 170 | GlobeNewswire (Europe) | Secured $147.6 million in proceeds and committed capital following completion of strategic transactions and concurrent public and private equity offerings, led by $71.6 million in committed capital... ► Artikel lesen | |
| 10.11.25 | Orchestra BioMed Holdings, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| ORCHESTRA BIOMED Aktie jetzt für 0€ handeln | |||||
| 03.11.25 | Orchestra BioMed files secondary offering of ~8M shares | 2 | Seeking Alpha | ||
| 28.10.25 | Orchestra BioMed, Terumo Sign $30 Million Strategic Agreements For Virtue SAB | 5 | RTTNews | ||
| 28.10.25 | Orchestra BioMed, Terumo terminate drug-eluting balloon distro deal in $30M agreement | 2 | MassDevice | ||
| 28.10.25 | Orchestra BioMed Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 27.10.25 | Orchestra BioMed enrolls first patient in Sirolumus AngioInfusion balloon trial | 1 | MassDevice | ||
| 27.10.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial | 247 | GlobeNewswire (Europe) | Orchestra BioMed's Virtue® Sirolimus AngioInfusionTM Balloon ("Virtue SAB") is the first non-coated drug-eluting balloon system designed to deliver a large liquid dose of proprietary extended-release... ► Artikel lesen | |
| 09.10.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit | 2 | GlobeNewswire (USA) | ||
| 11.09.25 | Piper Sandler reiterates Overweight rating on Orchestra BioMed stock | 3 | Investing.com | ||
| 11.09.25 | Piper Sandler bestätigt "Overweight"-Rating für Orchestra BioMed | - | Investing.com Deutsch | ||
| 04.09.25 | Orchestra BioMed Holdings, Inc.: Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout | 2 | GlobeNewswire (USA) | ||
| 04.09.25 | Orchestra BioMed stock price target lowered to $10 at H.C. Wainwright | 1 | Investing.com | ||
| 26.08.25 | Orchestra BioMed reports positive data on blood pressure therapy | 1 | Investing.com |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MOONLAKE IMMUNOTHERAPEUTICS | 18,610 | +29,69 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| CG ONCOLOGY | 54,30 | +29,49 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| AKTIS ONCOLOGY | 22,460 | 0,00 % | Aktis Oncology: Erster US-Börsengang des Jahres - die Hintergründe | Die Wall Street kann sich in Kürze über ein weiteres Biotech-Unternehmen freuen. Der Radiopharma-Spezialist Aktis Oncology strebt an die Nasdaq und will mit dem Listing einen dreistelligen Millionen-Dollar-Betrag... ► Artikel lesen | |
| QIAGEN | 41,230 | -0,15 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 26,245 | +12,74 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| VENTYX BIOSCIENCES | 13,805 | -0,18 % | Ventyx Biosciences und BioAge Labs: Tenbagger-Rendite im No Brainer Club! | Mit Ventyx Biosciences feiert der No Brainer Club eine waschechte Tenbagger-Empfehlung: Nach Übernahmegerüchten springt die Aktie heute im regulären Handel zunächst um rund 30% nach oben, bevor sie... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 24,250 | -4,19 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines... ► Artikel lesen | |
| ALUMIS | 19,550 | +7,59 % | What's Going On With Alumis Stock Thursday? | ||
| ERASCA | 6,705 | +14,81 % | What's Going With Cancer Biotech Erasca Stock On Thursday? | ||
| AVIDITY BIOSCIENCES | 72,39 | +0,06 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| ARCELLX | 66,31 | +3,11 % | UBS initiates Arcellx stock coverage with Buy rating, $100 price target | ||
| ARS PHARMACEUTICALS | 13,130 | +19,91 % | Weekly Buzz: ARS Pharma's Neffy Goes East, SLS Advances, A Signal Of Hope For IFRX? | LONDON (dpa-AFX) - Despite the typical year-end slowdown, the week saw a steady stream of high-impact news, highlighted by global approvals, clinical trial readouts, new product launches, and... ► Artikel lesen | |
| COGENT BIOSCIENCES | 35,330 | -0,67 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis | WALTHAM, Mass. and BOULDER, Colo., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| TANGO THERAPEUTICS | 11,820 | +6,92 % | Tango Therapeutics Sub, Inc: Tango Therapeutics Announces CEO Transition: Barbara Weber to Retire, Malte Peters Appointed Successor | Founding CEO Barbara Weber, M.D. to become executive chair of the board of directorsMalte Peters, M.D., current board member, appointed President and Chief Executive Officer, effective immediately... ► Artikel lesen | |
| REGENCELL BIOSCIENCE | 46,240 | +11,18 % | Regencell Bioscience is the top performing pharma stock YTD |
ORCHESTRA BIOMED HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,040 (-0,83 %) liegt der Kurs bei 4,800 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ORCHESTRA BIOMED HOLDINGS INC finden Sie auf Wallstreet Online.